<DOC>
	<DOCNO>NCT00639821</DOCNO>
	<brief_summary>This study investigate mucosal gene expression defect associate active Crohn 's disease ( CD ) ulcerative colitis ( UC ) , studied effect infliximab induce downregulation inflammation mucosal heal abnormality , use whole genome gene expression microarrays .</brief_summary>
	<brief_title>Mucosal Gene Expression Defects IBD</brief_title>
	<detailed_description>Infliximab , monoclonal IgG1 antibody pro-inflammatory cytokine tumor necrosis factor-alpha ( TNF-Î± ) , first efficacious biological therapy IBD . Infliximab dramatically improve quality life IBD patient . Besides induce maintain remission refractory IBD patient , infliximab achieve new treatment goal intestinal mucosal heal reduction hospitalization surgeries long-term . However , 30 % IBD patient respond costly therapy potentially harmful therapy , extra 20-30 % response incomplete . The mechanism resistance infliximab unknown predictor response infliximab currently lack . The aim study investigate mucosal gene expression defect associate active Crohn 's disease ( CD ) ulcerative colitis ( UC ) , study effect infliximab induce downregulation inflammation mucosal heal abnormality , use whole genome gene expression microarray technology endoscopic-derived intestinal mucosal biopsy control individual patient active IBD , first infliximab treatment . Sixty-one patient inflammatory bowel disease , 19 Crohn 's colitis , 18 Crohn 's ileitis 24 UC , undergo colonoscopy biopsy 4-6 week first infliximab treatment . Response infliximab define base endoscopic histologic finding . A control group 12 individual also included.Total RNA isolated biopsy , label hybridize Affymetrix HGU133plus2.0 Array . Microarray data analyze use Bioconductor software Ingenuity Pathway Analysis software . Quantitative real time RT-PCR immunohistochemistry use confirm microarray data .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Clinical diagnosis inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) Patients inflammatory bowel disease refractory corticosteroid and/or immunosuppression never treat biological therapy ( antiTNF treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Gene expression microarray</keyword>
	<keyword>Inflammatory bowel disease</keyword>
	<keyword>Infliximab</keyword>
</DOC>